He Li

Dr. He Li


Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
11 December 2024 in Neurology and Therapy
Verified
Journal Article
Open access
PDF file
YHYibin Hu
Yibin Hu
SWShengxian Wu
Shengxian Wu
HZHaixuan Zhang
Haixuan Zhang
KWKangfeng Wang
Kangfeng Wang
LZLijuan Zhang
Lijuan Zhang
HLHe Li
He Li
Background Currently, there is limited evidence on the efficacy and safety of various thrombolytic drugs at different dosages for the treatment of acute ischemic stroke (AIS). From current randomized clinical trials, the optimal type and dosage of thrombolytics for patients with AIS are unclear. Methods This systematic review was registered in PROSPERO (CRD42024563757). We searched four databases using a combination of keywords that contained various intravenous thrombolytics, as well as acute ischemic stroke. Only data from participants with AIS treated with various intravenous thrombolytics within the 4.5-h time window were included. Among initially identified studies, 16 met the selection criteria. Network meta-analysis was conducted for efficacy (90 day modified Rankin scale score) and safety (intracranial hemorrhage events, mortality at 90 days) using Stata 17.0 software, with a fixed-effects model. Cochrane risk of bias tool assessed all risk of bias domains, and the CINeMA Evidence Assessment Tool evaluated the level of evidence for each outcome. Results A total of 9056 studies were retrieved through the literature search, and 12,792 patients screened from 16 randomized controlled trials were included in the network meta-analysis. The risk of bias in the included studies ranged from moderate to low. The network meta-analysis results indicated that reteplase at 18 + 18 mg ranked highest in efficacy, though its safety was lower compared to 0.25 mg/kg tenecteplase and alteplase. The dose of 0.25 mg/kg tenecteplase emerged as the optimal dose, demonstrating both superior efficacy and a lower risk of bleeding compared to alteplase, making it a potential alternative to alteplase. The dose of 50 mg prourokinase was associated with the highest risk of symptomatic intracranial hemorrhage and was inferior to reteplase in terms of both efficacy and safety. The CINeMA Evidence Assessment Tool identified one outcome with a high level of evidence, several with moderate levels, and the remainder with low levels. Conclusions Reteplase at 18 + 18 mg may be more suitable for patients with lower incidence of adverse events evaluated by physicians. Compared to 0.9 mg/kg alteplase, 0.25 mg/kg tenecteplase is more effective, with the lowest risk of intracranial hemorrhage. However, as tenecteplase’s dosages increase (0.32 mg/kg and 0.4 mg/kg), its efficacy in improving neurological deficits decreases, while the risk of intracranial hemorrhage and death (especially at 0.4 mg/kg) increases. Clinicians are supposed to carefully assess the needs of patients with AIS and the risks then choose decent thrombolytics.

19 June 2024 in Heliyon
Verified
Journal Article
Open access
YMYiZheng Ma
YiZheng Ma
JHJingBo Han
JingBo Han
KWKangFeng Wang
KangFeng Wang
HHHuan Han
Huan Han
YHYiBin Hu
YiBin Hu
LZLijuan Zhang
Lijuan Zhang
Atherosclerosis (AS) is a chronic inflammatory disease resulting from dysregulated lipid metabolism, constituting the pathophysiological foundation of cardiovascular and cerebrovascular diseases. AS has a high incidence rate and mortality rate worldwide. As such, traditional Chinese medicine (TCM) has been widely used recently due to its stable therapeutic effect and high safety. Ganoderma lucidum polysaccharides (GLP) are the main active ingredients of Ganoderma lucidum, a Chinese herbal medicine. Research has also shown that GLP has anti-inflammatory and antioxidant properties, regulates gut microbiota, improves blood glucose and lipid levels, and inhibits obesity. Most of the current research on GLP anti-AS is focused on animal models. Thus, its clinical application remains to be discovered. In this review, we combine relevant research results and start with the pathogenesis and risk factors of GLP on AS, proving that GLP can prevent and treat AS, providing a scientific basis and reference for the future prevention and treatment of AS with GLP.

19 February 2024 in Frontiers in Neurology
Verified
Journal Article
Open access
PDF file
YCYiRan Cheng
YiRan Cheng
CLChangNing Liu
ChangNing Liu
SLShanShan Li
ShanShan Li
MMMiao Miao Meng
Miao Miao Meng
HLHe Li
He Li
Objective: Argatroban is a highly promising drug for the treatment of acute ischemic stroke (AIS), but there is currently insufficient strong evidence regarding the efficacy and safety of using Argatroban in the treatment of AIS. Therefore, we conducted a systematic review and meta-analysis to evaluate the effectiveness and safety of Argatroban in the treatment of AIS.Methods: Articles on PubMed, Embase and the Cochrane Library databases were searched from these websites’ inceptions to 2th February 2023. Randomized controlled trials and observational studies on Argatroban therapy for acute ischemic stroke were included. Meta-analyses were conducted using a random-effects model.Results: Fourteen studies involving 10,315 patients were included in the meta-analysis. The results showed a significant reduction in the rate of early neurological deterioration (END) in the Argatroban group compared with the control group (OR = 0.47, 95% CI: 0.31–0.73, I2 = 15.17%). The rates of adverse events were no significant difference between the two groups (ICH: OR = 1.02, 95% CI: 0.68–1.51, I2 = 0.00%; major extracranial bleeding: OR = 1.22, 95% CI: 1.01–1.48, I2 = 0.00%; mortality: OR = 1.16, 95% CI: 0.84–1.59, I2 = 0.00%). However, the rates of mRS score of 0–1 (OR = 1.38, 95% CI: 0.71–2.67, I2 = 77.56%) and mRS score of 0–2 (OR = 1.18, 95% CI: 0.98–1.42, I2 = 0.00%) during the 90 days did not significantly improved in the Argatroban group. Subgroup analyses showed that the rate of END (OR = 0.41, 95% CI: 0.26–0.65, I2 = 2.77%) and mRS score of 0–2 (OR = 1.38, 95% CI: 1.06–1.81, I2 = 0.00%) had significantly improved when the intervention group adopted Argatroban plus Antiplatelet.Conclusion: Argatroban can improve neurological deterioration, with a low incidence of adverse events such as bleeding and death, and general analysis showed no improvement in mRS. However, subgroup analysis suggests that compared to mono-antiplatelet therapy, combination therapy of Argatroban combined with antiplatelet therapy significantly reduced the incidence of END and improved mRS scores. After using Argatroban, there was no increase in the risk and mortality of intracranial hemorrhage and other bleeding sites.

30 November 2023 in BMC Neurology
Verified
Journal Article
Open access
PDF file
HLHe Li
He Li
YCYiRan Cheng
YiRan Cheng
WTWei Tang
Wei Tang
YHYiBin Hu
YiBin Hu
GJGeHui Jia
GeHui Jia
KWKangFeng Wang
KangFeng Wang
Diabetic striatopathy (DS) is a rare central nervous system complication of diabetes mellitus, characterized mainly by non-ketotic hyperglycemia and lateralized involuntary movements. Patients with diabetic striatopathy manifested solely by subacute cognitive decline were rarely reported. In this paper, we report a patient with DS who presented solely with subacute cognitive decline without involuntary movements, and cranial CT showed bilateral high density in the basal ganglia. In contrast, SWI showed microhemorrhages in the right caudate nucleus head. After one week of treatment, including glycemic control, the patient showed significant improvement in cognitive function, while a repeat cranial CT showed improved hyperdensity in the right basal ganglia region. 1 month later, at telephone follow-up, the patient’s symptoms did not recur.

31 October 2024 in Brain and Behavior
Verified
Journal Article
Open access
YWYa‐Han Wang
Ya‐Han Wang
PDPeng‐Li Ding
Peng‐Li Ding
KZKai‐Xin Zhang
Kai‐Xin Zhang
XXXiang-Qing Xu
Xiang-Qing Xu
HLHe Li
He Li
Purpose: The abnormal central glucose metabolism in Alzheimer's disease (AD) is related to the brain–gut axis. This study aims to explore the target of Danggui‐Shaoyao‐San (DSS) in improving cognitive impairment.Method: This study analyzed the differences in mice intestinal flora by 16S rRNA sequencing. The cognitive protective effects of DSS were observed through the Morris water maze and the new object recognition. The mitigation effects of DSS on Aβ and p‐tau, regulatory effects on glucose metabolism targets, and intestinal structure effects were observed through brain and colon slices staining. The differences in neural ultrastructure were compared by transmission electron microscopy.Finding: The results showed that DSS affected the composition of intestinal dominant bacteria and bacteria genera and regulated the abundance of intestinal bacteria in AD mice. DSS improved the behavior of AD mice, alleviated the deposition of AD pathological products in the brain and colon, regulated the expression of glycometabolism‐related proteins, and improved the colon barrier structure and neural ultrastructure in the brain of mice with AD.Conclusion: Our findings suggest that DSS may affect AD central glucose metabolism and improve cognition by regulating the gut–brain axis.

16 April 2025 in Phytomedicine
Verified
Journal Article
Closed access
HJHanrui Ji
Hanrui Ji
ZDZhizhi Dong
Zhizhi Dong
YYYanan Yang
Yanan Yang
WCWenqiang Cui
Wenqiang Cui
JHJingbo Han
Jingbo Han
SWShengxian Wu
Shengxian Wu